STADA and Alvotech Introduces Uzpruvo (Biosimilar, Stelara) Across the EU
Shots:
- The company has introduced Uzpruvo, biosimilar of Stelara (ustekinumab) across the EU to treat gastroenterology, dermatology & rheumatology indications. Uzpruvo is available in a pre-filled syringes with a thinner needle & is latex-free to avoid allergic reactions
- Further EU launches are expected in the upcoming mos., pending national price approvals through a fully European supply chain
- Uzpruvo was approved across the EU in Jan 2024 to treat adults with Crohn’s disease & psoriatic arthritis plus plaque psoriasis in adults & children (from 6yrs.)
Ref: Alvotech | Image: STADA
Related News:- STADA and Alvotech’s Uzpruvo (Biosimilar, Stelara) Obtains EC’s Approval for Immune-Mediated Diseases
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
A passionate content writer with expertise in delivering high-quality and engaging content, Dipanshu is a keen reader and a versatile writer. Dipanshu dedicatedly covers news ranging from biopharma, life sciences, biotech, and MedTech to diagnostics and animal health companies. He can be contacted at connect@pharmashots.com
